LEADER 03167nam 2200625Ia 450 001 9910465116503321 005 20210507005443.0 010 $a0-300-18943-5 024 7 $a10.12987/9780300189438 035 $a(CKB)2560000000102350 035 $a(EBL)3421247 035 $a(SSID)ssj0000893364 035 $a(PQKBManifestationID)12450775 035 $a(PQKBTitleCode)TC0000893364 035 $a(PQKBWorkID)10906698 035 $a(PQKB)11211369 035 $a(StDuBDS)EDZ0000157993 035 $a(MiAaPQ)EBC3421247 035 $a(DE-B1597)486260 035 $a(OCoLC)847527246 035 $a(DE-B1597)9780300189438 035 $a(Au-PeEL)EBL3421247 035 $a(CaPaEBR)ebr10718703 035 $a(CaONFJC)MIL496059 035 $a(OCoLC)923604036 035 $a(EXLCZ)992560000000102350 100 $a20121220d2013 uy 0 101 0 $aeng 135 $aurnnu---|u||u 181 $ctxt 182 $cc 183 $acr 200 10$aWriting history in the age of biomedicine$b[electronic resource] /$fRoger Cooter with Claudia Stein 210 $aNew Haven $cYale University Press$d2013 215 $a1 online resource (365 p.) 300 $aDescription based upon print version of record. 311 0 $a0-300-18663-0 320 $aIncludes bibliographical references and index. 327 $tFront matter --$tContents --$tPreface --$tAcknowledgments --$t1. The End? --$t2. Anticontagionism and History's Medical Record --$t3. "Framing" the End of the Social History of Medicine --$t4. The Turn of the Body --$t5. Coming into Focus --$t6. Visual Objects and Universal Meanings --$t7. The Biography of Disease --$t8. Inside the Whale --$t9. Cracking Biopower --$t10. The New Poverty of Theory --$tNotes --$tBibliography --$tIndex 330 $aA collection of ten essays paired with substantial prefaces, this book chronicles and contextualizes Roger Cooter's contributions to the history of medicine. Through an analysis of his own work, Cooter critically examines the politics of conceptual and methodological shifts in historiography. In particular, he examines the "double bind" of postmodernism and biological or neurological modeling that, together, threaten academic history. To counteract this trend, suggests Cooter, historians must begin actively locating themselves in the problems they consider. The essays and commentaries constitute a kind of contour map of history's recent trends and trajectories-its points of passage to the present-and lead both to a critical account of the discipline's historiography and to an examination of the role of intellectual frameworks and epistemic virtues in the writing of history. 606 $aMedicine$xHistory$y20th century 606 $aBiology$xResearch 608 $aElectronic books. 615 0$aMedicine$xHistory 615 0$aBiology$xResearch. 676 $a808.06/661 700 $aCooter$b Roger$0993957 701 $aStein$b Claudia$0981998 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910465116503321 996 $aWriting history in the age of biomedicine$92451221 997 $aUNINA LEADER 01854nam 2200481 450 001 9910130516603321 005 20160620170946.0 035 $a(CKB)3400000000019696 035 $a(ItFiC)it 08908609 035 $a(SSID)ssj0000576734 035 $a(PQKBManifestationID)12185436 035 $a(PQKBTitleCode)TC0000576734 035 $a(PQKBWorkID)10558348 035 $a(PQKB)10624115 035 $a(EXLCZ)993400000000019696 100 $a20091204d2007 uy 0 101 0 $aita 181 $ctxt 182 $cc 183 $acr 200 00$aAlberti e la cultura del Quattrocento$b[electronic resource] $eatti del convegno internazionale del Comitato nazionale VI centenario della nascita di Leon Battista Alberti ... /$fa cura di Roberto Cardini, Mariangela Regoliosi 210 $aFirenze $cPolistampa$d2007 215 $a2 v. (915 p.) 225 0$aStrumenti ;$v5 225 0$aEdizione nazionale delle opere di Leon Battista Alberti 300 $aProceedings, Florence, 2004. 300 $aL. B. Alberti (1404-1472). 311 $a88-596-0352-8 320 $aIncludes bibliographical references. 517 $aAlberti e la cultura del Quattrocento : atti del convegno internazionale del Comitato nazionale VI centenario della nascita di Leon Battista Alberti ... 517 $aAlberti e la cultura del Quattrocento 607 $aItaly$xIntellectual life$y1268-1559$vCongresses 676 $a850 700 $aCardini$b Roberto$0154419 701 $aCardini$b Roberto$0154419 701 $aRegoliosi$b Mariangela$0154742 712 02$aComitato nazionale VI centenario della nascita di Leon Battista Alberti, Convegni internazionali Staff 801 0$bItFiC 801 1$bItFiC 906 $aBOOK 912 $a9910130516603321 996 $aAlberti e la cultura del Quattrocento$92430433 997 $aUNINA LEADER 01529nam 2200421 450 001 9910709771703321 005 20180621141801.0 035 $a(CKB)5470000002472527 035 $a(OCoLC)1041189966 035 $a(EXLCZ)995470000002472527 100 $a20180621d2011 ua 0 101 0 $aeng 135 $aurmn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEducation supports racial and ethnic equality in STEM /$fby David Beede [and six others] 210 1$aWashington, DC :$cU.S. Department of Commerce, Economics and Statistics Administration,$d2011. 215 $a1 online resource (11 pages) $ccolor illustrations 225 1 $aESA issue brief ;$v#11-05 300 $a"September 2011." 606 $aMinorities in science$zUnited States$vStatistics 606 $aMinorities in technology$zUnited States$vStatistics 606 $aMinorities in engineering$zUnited States$vStatistics 606 $aMinorities in mathematics$zUnited States$vStatistics 608 $aStatistics.$2lcgft 615 0$aMinorities in science 615 0$aMinorities in technology 615 0$aMinorities in engineering 615 0$aMinorities in mathematics 700 $aBeede$b David N.$01402299 712 02$aUnited States.$bEconomics and Statistics Administration, 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910709771703321 996 $aEducation supports racial and ethnic equality in STEM$93527084 997 $aUNINA LEADER 05175nam 2200625Ia 450 001 9910840957503321 005 20230607221205.0 010 $a1-281-76404-3 010 $a9786611764043 010 $a3-527-61302-1 010 $a3-527-61303-X 035 $a(CKB)1000000000377124 035 $a(EBL)481814 035 $a(OCoLC)261222514 035 $a(SSID)ssj0000212533 035 $a(PQKBManifestationID)11174885 035 $a(PQKBTitleCode)TC0000212533 035 $a(PQKBWorkID)10138183 035 $a(PQKB)11454388 035 $a(MiAaPQ)EBC481814 035 $a(EXLCZ)991000000000377124 100 $a20001125d2001 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel therapeutic proteins $eselected case studies /$fedited by Klaus Dembowsky and Peter Stadler 210 $aWeinheim ;$aNew York $cWiley-VCH$dc2001 215 $a1 online resource (388 p.) 300 $aDescription based upon print version of record. 311 $a3-527-30270-0 320 $aIncludes bibliographical references and index. 327 $aNovel Therapeutic Proteins; Foreword; Preface; Contents; Introduction and Overview; 1 Medical Applications of Recombinant Proteins in Humans; 1.1 Introduction; 1.2 Presently Approved Biotech Products; 1.3 Biotechnology Products in Clinical Development; 1.4 Specific Diseases and Applications; 1.4.1 Myocardial Infarction and Stroke; 1.4.2 Heart Failure; 1.4.3 Fibrosis; 1.4.4 Osteoporosis; 1.4.5 Obesity, Insulin Resistance, and Non-Insulin Dependent (Type II) Diabetes; 1.4.6 Sepsis; 1.4.7 Immunoenhancement; 1.4.7.1 Tumor Therapy; 1.4.7.2 Vaccines; 1.4.8 Immune Deviation 327 $a1.4.9 Multiple Sclerosis (MS)1.4.10 Psoriasis; 1.4.11 Arthritis; 1.4.12 Inflammatory Bowel Disease; 1.4.13 Allergy and Asthma; 1.4.14 Replacement Therapies; 1.4.15 Viral Infections; 1.4.16 Reproductive Medicine .; 1.4.17 Other; 1.5 Conclusion; 1.6 References; Recombinant Hormones; 2 Clinical Applications of Recombinant Human Erythropoietin; 2.1 Structure of Human Erythropoietin; 2.2 General Principles; 2.3 Medical Applications of Recombinant Human EPO; 2.3.1 The Anemia of Chronic Renal Failure (CRF); 2.3.2 Acquired Immunodeficiency Syndrome (AIDS) 327 $a2.3.3 Chemotherapy Induced Anemia of Non-Hematologic Malignancies 2.3.4 The Perioperative Setting; 2.3.4.1 Recombinant Human EPO without Autologous Blood Donation; 2.3.4.2 Recombinant Human EPO as an Adjunct to Autologous Bood Donation; 2.3.5 The Anemia of Prematurity; 2.3.6 The Anemia of Hematologic Malignancies; 2.3.7 Myelodysplastic Syndromes and Other Hematologic Stem Cell Disorders; 2.3.8 Bone Marrow Transplantation (BMT); 2.3.9 The Hemoglobinopathies; 2.3.10 The Anemia of Chronic Inflammation; 2.4 Patient Response and Medical Economics 327 $a2.5 Pharmacokinetics : Dosage, Routes of Administration. and Effect Monitoring 2.6 Iron Supplementation during rhEPO Treatment; 2.7 Future Directions; 2.8 References; 3 Human Recombinant Growth Hormone; 3.1 Introduction; 3.2 Hypothalamic Regulation; 3.2.1 Somatostatin; 3.2.2 Growth Hormone Releasing Hormone; 3.2.3 Other Neurotransmitters; 3.3 Peripheral Regulation of GH; 3.4 Mechanisms of Action of GH; 3.4.1 GH Receptor; 3.4.2 Metabolic Effects; 3.4.3 Insulin Growth Factors (IGF); 3.4.3.1 Circulation of IGF; 3.4.3.2 Receptors of IGF; 3.4.3.3 Actions of IGF; 3.5 GH Effects on Growth 327 $a3.5.1 Dwarfism 3.5.2 Gigantism; 3.5.3 Acromegaly; 3.5.4 GH Deficiency in the Adult; 3.6 Production of GH; 3.6.1 Preparations Obtained by Extractions; 3.6.2 Genetic Engineering of GH; 3.6.2.1 Synthesis in Prokaryotic Cells; 3.6.2.2 Second Synthetic Procedure for GH Synthesis; 3.6.2.3 Third Synthetic Procedure for GH Synthesis; 3.6.2.4 Synthesis of hGH in Eukaryotic Cells; 3.7 Therapy with GH; 3.7.1 Use of rhGH in the Treatment of GH Defiency; 3.7.2 Use of rhGH in Chronic Renal Failure (CRF); 3.7.3 Use of rhGH in Turner's Syndrome; 3.7.4 Use of GH in Different Catabolic States and in AIDS 327 $a3.8 References 330 $aThis book describes medical applications of recombinant proteins and monoclonal antibodies, some of which have already been on the market for several years while others have only recently been launched. It also highlights the manufacturing processes for individual products, the strategies that were taken by companies in the clinical development, and the hurdles that were encountered in clinical trials and had to be overcome before approval by regulatory authorities. Finally, this book illustrates strategies to modify and improve the pharmacodynamic and pharmacokinetic properties of naturally o 606 $aGene therapy$vCase studies 606 $aRecombinant proteins$vCase studies 615 0$aGene therapy 615 0$aRecombinant proteins 676 $a615.3 676 $a660.6 701 $aStadler$b Peter$cDr.$0408042 701 $aDembowsky$b Klaus$01727843 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910840957503321 996 $aNovel therapeutic proteins$94135681 997 $aUNINA